<DOC>
	<DOCNO>NCT01743521</DOCNO>
	<brief_summary>To examine safety efficacy response guide triple therapy ( PEG-IFN , Ribavirin , Telaprevir ) treatment early chronic Hepatitis C Virus ( HCV ) infection .</brief_summary>
	<brief_title>DAA Based Therapy Recently Acquired Hepatitis C ( DARE-C )</brief_title>
	<detailed_description>DARE-C prospective open label multi-centre pilot study examine safety efficacy response guide triple therapy ( PEG-IFN , Ribavirin Telaprevir ) treatment early chronic HCV genotype 1 infection individual without HIV infection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Provision write , informed consent . 2 . HCV genotype 1 infection 3 . Quantifiable HCV RNA screen baseline ( &gt; 10,000 IU/ml ) 4 . Recent hepatitis C infection estimate duration Infection &gt; 6 month â‰¤ 18 month define A ) ) First antiHCV antibody HCV RNA positive within previous 6 month ii ) Documented antiHCV antibody negative HCV RNA negative within 24 month prior antiHCV antibody positive result OR B ) ) First antiHCV antibody HCV RNA positive within previous 6 month ii ) acute clinical hepatitis ( jaundice ALT &gt; 10 X ULN ) within 12 month prior first positive HCV antibody HCV RNA cause acute hepatitis identifiable 5 . Compensated liver disease ( ChildPugh A ) 6 . Negative pregnancy test screen 24 hour prior first dose study drug . 7 . If heterosexually active , female subject childbearing potential nonvasectomized male subject female partner childbearing potential must agree use 2 effective contraceptive screen onwards 6 month ( female subject ) 7 month ( male subject ) RBV therapy end . Note : Hormonal contraceptive may continue may reliable telaprevir dose 2 month follow cessation telaprevir . Therefore , subject agree use 2 effective nonhormonal method contraception telaprevir combination therapy 2 month last intake telaprevir . As two month completion telaprevir hormonal contraceptive use one two required effective method birth control . 8 . Subject judge medically stable basis physical examination , medical history vital sign . 9 . Adequate English provide write , informed consent provide reliable response study interview Additional inclusion criterion HIV positive individual Confirmed HIV infection &gt; 6 month duration CD4 &gt; 200 cells/mm3 HIV &lt; 50 c/ml stable antiretroviral therapy ( ART ) least 3 month prior treatment Or CD4 &gt; = 500 cells/mm3 HIV viral load ( VL ) &lt; 100,000 ART If ART must take regimen contain accepted* combination follow drug : tenofovir ( TDF ) , lamivudine ( 3TC ) , emtricitabine ( FTC ) , efavirenz ( EFV ) , abacavir ( ABC ) , raltegravir ( RAL ) , etravirine ( ETV ) , rilpivirine ( RIL ) , ritonavir boost atazanavir ( r/ATZ ) * Combination must support current HIV treatment guideline Individuals consider study investigator unlikely participate intensive followup and/or unwilling provide extra blood sample Current inject drug use ( inject within previous 4 week ) Standard exclusion Pegylatedinterferon ( PEGIFN ) , Ribavirin ( RBV ) Telaprevir ( TPV ) therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Individualised therapy</keyword>
	<keyword>Response-guided therapy</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>PEG-IFN</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Hepatitis</keyword>
</DOC>